EB-CAR30-NK
EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.
Overview
EB-CAR30-NK is a CAR-NK cell therapy developed by Beijing Biotech. Its target is CD30. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in thymoma and thymic carcinoma. The largest, NCT07598955, plans to enrol 36 participants with primary completion expected 2027-06-14. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"EB-CAR30-NK" OR ABSTRACT:"EB-CAR30-NK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EB-CAR30-NK, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentKC1036
Shares Thymoma and thymic carcinoma and the tags pipeline, ctgov-ingest.
- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.
- TreatmentAbexinostat
Shares the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares the tags pipeline, ctgov-ingest.
- TreatmentABT-301
Shares the tags pipeline, ctgov-ingest.
- TreatmentAcasunlimab
Shares the tags pipeline, ctgov-ingest.